Ribociclib-Induced Delayed Dermatological Reaction: Case Report of a Rare Adverse Effect and Review of Literature
Sign Up to like & getrecommendations! Published in 2023 at "Indian Journal of Medical and Paediatric Oncology"
DOI: 10.1055/s-0043-1766128
Abstract: Abstract Ribociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor approved in combination with endocrine-based therapy for the treatment of hormone receptor-positive (HR + )/human epidermal growth factor receptor 2-negative (HER2 − ) advanced or metastatic breast cancer. It… read more here.
Keywords: effect; induced delayed; ribociclib induced; ribociclib ... See more keywords
Effect of adenosine triphosphate on ribociclib-induced skin toxicity in rats
Sign Up to like & getrecommendations! Published in 2023 at "Cutaneous and Ocular Toxicology"
DOI: 10.1080/15569527.2023.2166524
Abstract: Abstract Purpose Ribociclib is a CDK4/6 inhibitor approved for the treatment of breast cancer; it inhibits the activity of CDK4/6 by competitively binding to adenosine 5'-triphosphate (ATP) binding sites. Although generally well-tolerated, ribociclib has been… read more here.
Keywords: induced skin; ribociclib induced; ribociclib; group ... See more keywords
Cyclin-dependent kinase 4/6 inhibitor ribociclib-induced colitis with a successful transition to palbociclib
Sign Up to like & getrecommendations! Published in 2025 at "BMJ Case Reports"
DOI: 10.1136/bcr-2024-263176
Abstract: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6Is), including ribociclib, are used alongside endocrine therapy for hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative metastatic breast cancer. Ribociclib-induced colitis is a rare drug reaction with unknown… read more here.
Keywords: cyclin dependent; ribociclib induced; dependent kinase; ribociclib ... See more keywords